3Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg, 1990,99 : 518-527.
4Landis RC, Haskard DO, Taylor KM. New antiinflammatory and plateletpreserving effects of aprotinin. Ann Thorac Surg, 2001,72: S1808-1813.
5Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmininduced platelet activation during cardiopulmonary bypass. Circulation,1997,96 : 569-574.
6Despotis GJ, Gravlee G, Filos K, et al. Antieoagulation monitoring during cardiac surgery: a review of current and emerging techniques.Anesthesiology, 1999, 91 : 1122-1151.
7Landis RC, Asimakopoulos G, Poullis M, et alThe antithrombotie and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg,2001, 72:2169-2175.
8Rich JB. The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg, 1998, 66(5 Suppl) :S6-11.
9Sodha NL, Boodhwani M, Bianchi C, et al. Aprotinin in Cardiac Surgery. Expert Rev Cardiovasc Ther, 2006, 4:151-160.
10Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery:erythropoietin and antifibrinolytics. Can J Anesth, 2001, 48:S24-S31.
